<DOC>
	<DOCNO>NCT02453802</DOCNO>
	<brief_summary>The purpose study , therefore , conduct prospective randomize control trial investigate blood-conservation effect TXA different TKA patient group rivaroxaban VTE prophylaxis , first group topical application , second group infusion third group placebo observe whether difference occurrence venous thromboembolism patient group venographic study</brief_summary>
	<brief_title>Comparison Topical Infusion Tranexamic Acid After Total Knee Arthroplasty</brief_title>
	<detailed_description>Investigators previous experience minimally invasive ( MIS ) TKA show intraoperative infusion TXA reduce 45 % postoperative blood loss need transfusion 20 % 4 % . However , orthopedic surgeon still hesitate use TXA systemically TKAs especially high risk patient potential increase thromboembolic event follow surgery . Because concern , recently , report demonstrate cost-effectiveness topical application TXA TKA patient . However , report compare topical TXA placebo TKA patient , intravenous TXA . Recently , Georgiadis et al . conduct double-blind , randomize control clinical trial demonstrate similar transfusion rate perioperative blood loss topical administration intravenous injection TXA TKA patient . There significant safety difference two group . Low-molecular weight heparin ( LMWH ) use thromboembolism prophylaxis study . Recently , chemical VTE prophylaxis rivaroxaban approve standard care TKA superior convenience efficacy VTE prophylaxis LMWH TKAs . However , direct blockage formation thrombin prothrombin rivaroxaban , increase postoperative bleeding report . There little study investigate blood-conservation effect TXA TKA patient either infusion topical application rivaroxaban use VTE prophylaxis .</detailed_description>
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Osteoarthritis , Knee</mesh_term>
	<mesh_term>Rivaroxaban</mesh_term>
	<mesh_term>Tranylcypromine</mesh_term>
	<mesh_term>Tranexamic Acid</mesh_term>
	<criteria>Endstage arthritis knee Failure medical treatment rehabilitation Hemoglobin &gt; 10g/dl No use nonsteroid antiinflammatory agent one week operation Preoperative Hemoglobin â‰¦10 g/dl History infection intraarticular fracture affective knee Renal function deficiency ( GFR &lt; 55 ml/min/1.73m2 ) relative contraindicate venography Elevated liver enzyme , history liver cirrhosis , impair liver function coagulopathy ( include longterm use anticoagulant ) History deep vein thrombosis , ischemic heart disease stroke</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>Tranexamic Acid</keyword>
	<keyword>Total Knee Arthroplasty</keyword>
	<keyword>Rivaroxaban</keyword>
</DOC>